Décès par vindésine intrarachidienne = Death by intrathecal vindesineLa Revue Prescrire. 2007, Vol 27, Num 290, pp 912-912, issn 0247-7750, 1 p.Article

Antitumor properties of vindesine-monoclonal antibody conjugatesROWLAND, G. F; AXTON, C. A; MARSDEN, C. H et al.Cancer immunology and immunotherapy. 1985, Vol 19, Num 1, pp 1-7, issn 0340-7004Article

Razoxane and vindesine in advanced soft tissue sarcomas : Impact on metastasis, survival and radiation responseRHOMBERG, Walter; EITER, Helmut; SCHMID, Franz et al.Anticancer research. 2007, Vol 27, Num 5B, pp 3609-3614, issn 0250-7005, 6 p.Article

VINDESIN, EIN NEUES ZYTOSTATIKUM AUS DER REIHE DER VINCA-ALKALOIDE = VINDESINE, NOUVEAU CYTOSTATIQUE DE LA SERIE DES ALCALOIDES DE LA VINCAGOLDHIRSCH A; JOSS R; SONNTAG RW et al.1980; DTSCHE MED. WSCHR.; DEU; DA. 1980; VOL. 105; NO 26; PP. 931-935; BIBL. 41 REF.Article

Administration accidentelle intrathécale de vindésine : à propos de 2 cas mortels = Accidental intrathecal vindesine administration : A report of two casesNISSE, Patrick; CHARPENTIER, Julien; DUBOIS, Francois et al.Thérapie (Paris). 2007, Vol 62, Num 4, pp 360-361, issn 0040-5957, 2 p.Article

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatmentKRIS, M. G; GRALLA, R. J; KELSEN, D. P et al.Chest. 1985, Vol 87, Num 3, pp 368-372, issn 0012-3692Article

Cytotoxicity of etretinate and vindesineGAUKROGER, J. M; WILSON, L; MACKIE, R et al.British journal of cancer. 1985, Vol 52, Num 3, pp 369-375, issn 0007-0920Article

Differential in vitro association of vinca alkaloid-induced tubulin spiral filaments into aggregated spiralsVERDIER-PINARD, P; GARES, M; WRIGHT, M et al.Biochemical pharmacology. 1999, Vol 58, Num 6, pp 959-971, issn 0006-2952Article

Successful induction therapy of natural killer/cytotoxic T-lymphocyte cells in the treatment of Langerhans' cell histiocytosisHIROSE, M; KURODA, Y.International journal of hematology. 1999, Vol 69, Num 4, pp 272-273, issn 0925-5710Article

Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicinFIORE, J. J; KELSEN, D. P; GRALLA, R. J et al.Cancer treatment reports. 1985, Vol 69, Num 6, pp 591-594, issn 0361-5960Article

NEUROLOGICAL TOXICITY OF VINDESINE USED IN COMBINATION CHEMOTHERAPY OF 51 HUMAN SOLID TUMORSFOCAN C; OLIVER R; LE HUNG S et al.1981; CANCER CHEMOTHER. PHARMACOL.; ISSN 0344-5704; DEU; DA. 1981; VOL. 6; NO 2; PP. 175-181; BIBL. 60 REF.Article

LA VINDESINE: UN NOUVEAU CYTOSTATIQUEHULHOVEN R.1980; LOUVAIN MED.; BEL; DA. 1980; VOL. 99; NO 2; PP. 113-116; ABS. ENG; BIBL. 10 REF.Article

PHASE II TRIAL OF VINDESINE IN PATIENTS WITH MALIGNANT LYMPHOMASKLAROFF RB; STRAUSS D; YOUNG C et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 5; PP. 793-794; BIBL. 11 REF.Article

La vindésine dans les cancers stomatologiques = Vindesine in stomatologic tumorsSZPIRGLAS, H; MARNEUR, M; VAILLANT, J. M et al.La Presse médicale (1983). 1985, Vol 14, Num 7, pp 405-407, issn 0755-4982Article

Monoclonal antibodies for targeting chemotherapeutic agentsBALDWIN, R. W.Progress in experimental tumor research. 1985, Vol 29, pp 140-151, issn 0079-6263Article

The stability of five chemotherapy drugs stored frozen for use in the human tumor stem cell assayFRANCO, R; MILLER, T; KRAFT, T et al.International journal of cell cloning. 1985, Vol 3, Num 6, pp 424-426, issn 0737-1454Article

A VINDESINE-ANTI-CEA CONJUGATE CYTOTOXIC FOR HUMAN CANCER CELLS IN VITROJOHNSON JR; FORD CHJ; NEWMAN CE et al.1981; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1981; VOL. 44; NO 3; PP. 472-475; BIBL. 15 REF.Article

PHARMACOKINETICS OF VINDESINE AND VINCRISTINE IN HUMANS.OWELLEN RJ; ROOT MA; HAINS FO et al.1977; CANCER RES.; U.S.A.; DA. 1977; VOL. 37; NO 8 PART. 1; PP. 2603-2607; BIBL. 17 REF.Article

Pharmacokinetics of vindesine bolus and infusionJACKSON, D. V. JR; SAGAR SETHI, V; LONG, T. R et al.Cancer chemotherapy and pharmacology. 1984, Vol 13, Num 2, pp 114-119, issn 0344-5704Article

DETERMINATION OF TISSUE CONCENTRATIONS OF VINCA ALKALOIDS BY RADIOIMMUNOASSAYOWELLEN RJ; BLAIR M; VAN TOSH A et al.1981; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1981; VOL. 65; NO 5-6; PP. 469-475; BIBL. 16 REF.Article

ETUDE DE LA VINDESINE EN PERFUSION DE 5 JOURS DANS LE TRAITEMENT DES LEUCEMIES ET LYMPHOMESMARANINCHI D; GASTAUT JA; TUBIANA N et al.1981; BULL. CANCER; ISSN 0007-4551; FRA; DA. 1981; VOL. 68; NO 4; PP. 338-342; ABS. ENG; BIBL. 16 REF.Article

Patients ayant un cancer bronchique non à petites cellules = Patients with a non small cell lung cancerLa Revue Prescrire. 2008, Vol 28, Num DEC, pp 30-35, issn 0247-7750, 6 p., SUPArticle

Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancerIMAIZUMI, Munehisa.Lung cancer. 2005, Vol 49, Num 1, pp 85-94, issn 0169-5002, 10 p.Article

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancerNEGORO, S; MASUDA, N; TAKADA, Y et al.British journal of cancer. 2003, Vol 88, Num 3, pp 335-341, issn 0007-0920, 7 p.Article

Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan clinical oncology group study 9306SEKINE, Ikuo; NISHIWAKI, Yutaka; ISHIZUKA, Naoki et al.Journal of clinical oncology. 2002, Vol 20, Num 3, pp 797-803, issn 0732-183XArticle